Market Place
Sourcing Support
All News #Library
Others
Wugen Strengthens Executive Leadership Team
03 Jan 2024 //
GLOBENEWSWIRE
Wugen Announces CEO Transition
21 Mar 2023 //
BUSINESSWIRE
Wugen Presents Data Supporting Development of WU-NK-101 for Refractory AML
11 Dec 2022 //
BUSINESSWIRE
Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models
10 Sep 2022 //
BUSINESSWIRE
Wugen Announces Presentation of WU-NK-101 Preclinical Data at the ESMO Congress
04 Sep 2022 //
BUSINESSWIRE
Wugen Appoints Natalie Mount, Ph.D., as Chair of the Board of Directors
25 Aug 2022 //
BUSINESSWIRE
Wugen Receives FDA FTD and RPD Designations for WU-CART-007 in R/R T-ALL/LBL
19 Jul 2022 //
BUSINESSWIRE
WuXi ATU, Wugen Enter Manufacturing Partnership for Cancer Immunotherapies
16 Jun 2022 //
ASIAONE
Wugen to Present Preclinical Data on WU-NK-101 at EHA
12 May 2022 //
BUSINESSWIRE
Wugen to Present at the Innate Killer Summit 2022
24 Mar 2022 //
BUSINESSWIRE
Wugen says First Patient Dosed in P 1/2 Trial of WU-CART-007 in R/R T-ALL/LBL
15 Mar 2022 //
BUSINESSWIRE
Wugen to Present Virtually at Oppenheimer 32nd Annual Healthcare Conference
09 Mar 2022 //
BUSINESSWIRE
Wugen Presents New Preclinical Data Supporting Safety of WU-CART-007
11 Dec 2021 //
BUSINESSWIRE
Wugen Announces Data Presentation at The Society for Immunotherapy SITC)
09 Nov 2021 //
BUSINESSWIRE
Wugen Announces Data Presentation at 63rd ASH Annual Meeting
05 Nov 2021 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.